๐งฌ Replimune $REPL surged +130% on FDA adcom win โ formal approval decision due today
FDA advisers voted 10-3 in favor of Replimune's RP1 plus nivolumab for advanced melanoma patients who have failed prior anti-PD-1 therapy, sending $REPL rocketing over +130%. Today (August 2) is the official PDUFA decision date โ the FDA can issue approval or rejection at any time. An approval would be a meaningful new option for late-stage melanoma. Not financial advice. Are you holding through this binary FDA decision?
โก 54 buzzing
778 views
๐ 0 subscribed
